(Total Views: 420)
Posted On: 02/07/2018 6:06:37 PM
Post# of 72447
10-Q is out.
Kevetrin
"The Company believes that further pathways detail and clinical tumor responses would best be observable with more frequent and potentially higher drug exposure. Thus, the Company has decided to discontinue further enrollment into the current clinical trial and consider a similar trial when ongoing efforts result in the development of an oral formulation of Kevetrin for treating cancer."
Dr. Menon
"In early 2018, the Company approved steps to focus its efforts on clinical trials for its lead drug candidates. Among other changes, the salary of Dr. Krishna Menon, the Company’s President of Research, was reduced by 50%, and the Company anticipates further reductions to staff unrelated to clinical trials."
Shares outstanding: 145,688,782
https://www.sec.gov/Archives/edgar/data/13552...-index.htm
Kevetrin
"The Company believes that further pathways detail and clinical tumor responses would best be observable with more frequent and potentially higher drug exposure. Thus, the Company has decided to discontinue further enrollment into the current clinical trial and consider a similar trial when ongoing efforts result in the development of an oral formulation of Kevetrin for treating cancer."
Dr. Menon
"In early 2018, the Company approved steps to focus its efforts on clinical trials for its lead drug candidates. Among other changes, the salary of Dr. Krishna Menon, the Company’s President of Research, was reduced by 50%, and the Company anticipates further reductions to staff unrelated to clinical trials."
Shares outstanding: 145,688,782
https://www.sec.gov/Archives/edgar/data/13552...-index.htm
(2)
(0)
